IMUC
EOM Pharmaceuticals Holdings, Inc.
Set alert
- YTD
- +2.82%
- 1 year
- -59.44%
- Open
- 0.0726
- Prev close
- 0.075
- Mkt cap
- 9.23M
- Vol
- 180
- Avg vol
- 1.92K
- EPS
- 1.03
- P/E
- 0.07
- Div yield
- 0.00%
More statistics
- Low
- 0.0726
- High
- 0.0726
- Forward P/E
- -0.05
- Beta
- 2.71
- Short ratio
- 8.46
- Inst. own
- 4.30%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 30, 2019
- 50-d avg
- 0.108512
- 200-d avg
- 0.212253
- 1y target
- 5.00
Key statistics
- Market cap
- 1.34M
- Enterprise value
- -1.34M
- Trailing P/E
- 0.00
- Forward P/E
- -0.05
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.39
- EPS (TTM)
- -0.269
- Beta
- 2.71
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -9.22M
- Total cash
- 2.85M
- Total debt
- 0
- Return on equity
- -2312.00%
- Shares outstanding
- 41.94M
- Short % of float
- 4.15%
- 50-day average
- 0.108512
- 200-day average
- 0.212253
Analyst view
Consensus: hold
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 30, 2019
Expected Nov 30, 2019. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 30, 2019 | Dec 1, 2013 | 0.00 | — | — | — |
| Aug 13, 2018 | Jun 1, 2018 | 0.00 | -0.10 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 10, 2016 | Maxim Group | down | — | Hold |
| Dec 11, 2013 | McNicoll Lewis Vlak | down | — | Hold |
| Dec 11, 2013 | Roth Capital | down | — | Neutral |
About EOM Pharmaceuticals Holdings, Inc.
ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers. Its products include ICT-107, a dendritic cell (DC) immunotherapy for the treatment of diagnosed glioblastoma multiforme (GBM); ICT-140, a DC-based immunotherapy targets tumor associated antigens on ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs to treat recurrent GBM and other solid tumor cancers. The company is developing Steam-to-T-Cell immunotherapies for the treatment of cancer. It has license agreements with California Institute of Technology and The Johns Hopkins University. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Westlake Village, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- imuc.com
News
Your note
Sign in to keep a note on IMUC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| YU JOHN S | Director | Stock Award(Grant) | Jun 5, 2018 | 120,508 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Renaissance Technologies, LLC | 2.57% | 1,078,404 | 280.38K | Jun 29, 2018 |
| Vanguard Group, Inc. (The) | 0.68% | 285,154 | 74.14K | Jun 29, 2018 |
| Citadel Advisors LLC | 0.32% | 136,043 | 35.37K | Jun 29, 2018 |
| Virtu Financial LLC | 0.30% | 124,195 | 32.29K | Jun 29, 2018 |
| Wedbush Securities Inc | 0.21% | 86,530 | 22.50K | Jun 29, 2018 |
| First Allied Advisory Services, Inc. | 0.10% | 40,000 | 10.40K | Jun 29, 2018 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Invesco ETF Tr-Invesco Wilshire Micro Cap ETF | 0.03% | 12,365 | 3.21K | Jun 29, 2018 |
| Fidelity Extended Market Index Fund | 0.02% | 6,339 | 1.65K | Jun 29, 2018 |